-
Cabozantinib: RCC Workflows and Adaptation
2026-09-15
Build reproducible Cabozantinib and XL184 experiments around acute signaling inhibition, chronic adaptation, and motility phenotyping. This workflow connects phosphoproteomics with MET validation, angiogenesis assays, and practical troubleshooting for renal cell carcinoma research.
-
Biophysical Analysis of LNP Structure and Function
2026-09-15
Padilla and colleagues combine complementary solution-based biophysical methods to resolve lipid nanoparticle heterogeneity that conventional sizing assays often obscure. Their findings link formulation method, lipid composition, RNA loading, particle shape and translation performance, providing a stronger framework for interpreting mRNA delivery experiments.
-
Antimycin A4: From Natural Product to Assay Logic
2026-09-14
Antimycin A4 is an ATP-citrate lyase inhibitor with a second, mitochondria-centered mechanism that can complicate cellular interpretation. This evidence-led guide shows how to separate direct enzyme inhibition from respiratory-chain effects when designing metabolic assays.
-
Trilaurin Workflows for Biocatalysis and Delivery
2026-09-14
Trilaurin, also known as Glycerol Tridodecanoate, supports two distinct research workflows: lipase-enabled laurylamine synthesis and lipid-based protection of oral peptide, protein, and combination-drug payloads. Its C12 triacylglycerol structure also makes it a useful chain-length control when interpreting skin-sensitization assays.
-
DIDS: Workflows for Chloride and Tumor Stress
2026-09-13
DIDS supports concentration-aware studies of chloride transport, TRPV1 signaling, vascular tone, and tumor stress survival. This practical guide connects benchmark pharmacology with the PAME metastasis model while emphasizing solubility controls, matched vehicles, and orthogonal validation.
-
Piroxicam and Deracoxib in Canine Mammary Cancer Cells
2026-09-12
The reference study examined whether piroxicam and deracoxib directly suppress proliferation of the canine mammary carcinoma cell line CMT-U27, individually and in combination. Its main contribution is the evidence that combined COX inhibition enhanced cytotoxicity, promoted apoptosis at lower concentrations, and shifted cells toward G0/G1 arrest in vitro.
-
SD 169: A Mechanistic Guide to p38 MAPK Research
2026-09-12
SD 169 (indole-5-carboxamide) is a selective p38α/p38β inhibitor for dissecting stress, inflammatory, metabolic, and neural signaling. This guide focuses on a critical experimental distinction: acute kinase blockade versus phosphatase-driven resetting of p38 phosphorylation.
-
Firefly Luciferase mRNA: Causal Assay Design
2026-09-11
Firefly Luciferase mRNA (ARCA, 5-moUTP) can function as more than a bright reporter: it can help separate delivery, translation, RNA persistence, and cellular metabolism. This article presents a causal framework for gene expression, cell viability, and in vivo imaging workflows, informed by emerging RNA formulation research.
-
Deuterium-Labeled Degarelix: Synthesis and Significance
2026-09-11
The reference study reports a practical route to deuterium-labeled degarelix acetate by combining microwave-assisted H/D exchange of a naphthyl amino acid with solid-phase peptide synthesis. Its principal contribution is an accessible labeled intermediate and a 13-step sequence that supports the use of degarelix as a quantitatively traceable internal standard in pharmacokinetic and ADME studies.
-
α2-Adrenergic Receptor Agonist: B3465
2026-09-10
Explore how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine supports α2-adrenergic receptor research beyond routine protocols. This assay-centered guide connects receptor pharmacology, immune-mediated osteosarcoma recurrence models, product handling, and evidence-based experimental interpretation.
-
S-Adenosylmethionine (SAM) in Cell Assays
2026-09-10
Learn how S-Adenosylmethionine (SAM), SKU B3513, can be integrated into methylation, proliferation, viability, and cytotoxicity workflows without confusing metabolic effects with technical assay variation. This scenario-based guide covers concentration selection, solvent compatibility, interpretation, and product evaluation.
-
MLKL–Lysosome Signaling in Necroptosis
2026-09-09
The reference study identifies lysosomal membrane permeabilization as a critical intermediate between MLKL polymerization and necroptotic plasma membrane rupture. Its imaging, perturbation, and genetic experiments place cathepsin B downstream of lysosomal damage and show that blocking this protease can protect cells from necroptosis.
-
Adipose-Neural Signaling in Cardiac Arrhythmia
2026-09-09
Fan et al. developed a stem cell-based coculture model showing how epicardial adipose tissue can activate sympathetic neurons through leptin and drive NPY/Y1R-dependent electrical instability in cardiomyocytes. The study connects this pathway with NCX and CaMKII activity and supports its clinical relevance through epicardial adipose tissue and coronary sinus measurements in patients with atrial fibrillation.
-
U0126-EtOH for MEK1/2 Signaling Workflows
2026-09-08
U0126-EtOH is a selective MEK1/2 inhibitor for resolving whether ERK signaling drives neuronal injury, inflammation, or nonapoptotic cell death. This practical guide connects pathway pharmacology with reproducible dosing, assay design, and troubleshooting across oxidative stress, asthma, and leukemia models.
-
Isoproterenol Sulfate Dihydrate in Pacemaker Research
2026-09-08
Isoproterenol sulfate dihydrate is a non-selective beta-adrenergic agonist for controlled studies of beta-adrenergic receptor signaling, GPCR signaling, and the cAMP/PKA pathway. In human SAN-cardiac plexus assembloids, it can serve as an exogenous adrenergic perturbation, but it does not replace endogenous neural maturation mechanisms reported in the reference study.